- Familiar Therapeutics launched with $5 million in seed funding led by Pioneer Fund, Icehouse Ventures and BreakTHRU, with participation from angel investors.
- The company established 13 drug development programs in its first five months, including four lead programs and nine earlier-stage programs.
- Familiar has signed multiple pharmaceutical partnerships, filed a provisional patent and opened two investigational new animal drug (INAD) files with the FDA Center for Veterinary Medicine.
- Its pipeline spans oncology, neurology, cardiology, respiratory disease and immunology.
- The company’s lead program, FAM-010, targets canine hemangiosarcoma, with a pilot study scheduled to begin this fall at the University of Illinois College of Veterinary Medicine.
- Familiar aims to adapt medicines supported by existing human research for veterinary use, pursuing FDA approval for treatments in dogs and cats.
Familiar Therapeutics, a Redwood City, California-based animal health biotechnology company, has launched with $5 million in seed financing to develop treatments for dogs and cats using advances from human medicine.
The funding round was led by Pioneer Fund, Icehouse Ventures and BreakTHRU, a syndicate of animal health industry leaders and veterinarians, with additional participation from angel investors.
The company is focused on adapting pharmaceutical treatments developed through human research for veterinary applications, with the goal of bringing disease-modifying medicines to companion animals.
Addressing the Gap Between Human and Veterinary Medicines
According to Familiar, advances in human medicine over the past two decades have transformed treatment options for numerous chronic and life-threatening diseases. However, many of those developments have not translated into approved therapies for companion animals.
Dogs and cats develop many of the same diseases as humans, often involving similar underlying biological mechanisms.
Familiar noted that fewer than 10 new drugs receive FDA approval annually for companion animals, compared with more than 50 for human use.
For many serious veterinary conditions, practitioners continue to rely on human medications prescribed off-label, often without species-specific dosing and safety data.
Developing veterinary applications for existing medicines still requires dedicated clinical studies, manufacturing processes and FDA regulatory review.
Familiar’s business model focuses on licensing veterinary rights from pharmaceutical and biotechnology companies and managing the development, manufacturing and regulatory activities needed to bring those treatments to market.
By starting with compounds supported by years of human research, the company aims to shorten development timelines compared with the seven to ten years typically required to develop a new animal drug.
Thirteen Programs Established in First Five Months
During its first five months, Familiar established a pipeline consisting of four lead programs and nine earlier-stage programs for dogs and cats.
The company also reported signing multiple partnership and licensing agreements with biopharmaceutical companies, opening two investigational new animal drug files with the FDA Center for Veterinary Medicine and filing one provisional patent.
Its development pipeline spans oncology, neurology, cardiology, respiratory disease and immunology.
The $5 million seed investment will support clinical studies for the company’s lead programs and continued development of its broader pipeline.
Lead Program Targets Canine Hemangiosarcoma
Familiar’s most advanced program, FAM-010, is being developed for canine hemangiosarcoma, an aggressive cancer for which there is currently no FDA-approved treatment.
According to the company, median survival for dogs treated with surgery alone is less than two months.
Familiar is working toward developing FAM-010 as the first FDA-approved treatment for canine hemangiosarcoma.
A pilot study is scheduled to begin this fall at the University of Illinois College of Veterinary Medicine, led by Timothy M. Fan, DVM, PhD.
The company’s other lead programs target intervertebral disc disease, a common cause of back pain and paralysis in dogs; respiratory disorders affecting flat-faced breeds such as French Bulldogs and Pugs; and immune-mediated diseases.
All programs are being developed with the goal of obtaining full FDA approval.
Where eligible, Familiar may also pursue conditional approval, allowing veterinarians to use treatments for serious unmet medical needs while final effectiveness studies are completed.
Founders Bring Pharmaceutical Research and Development Experience
Familiar was founded by Elizabeth Iorns, PhD, and Dan Knox, MBA, who previously co-founded Science Exchange, a Y Combinator-backed research and development outsourcing platform used by major pharmaceutical companies.
The founders led Science Exchange through its acquisition in 2024.
Iorns, a cancer biologist, became personally interested in the gap between human and veterinary medicine after her French Bulldog, Lily, was diagnosed with a terminal brain tumor in 2020.
While reviewing scientific literature, she identified a checkpoint inhibitor that an academic research team had tested in dogs with brain tumors but that had not been commercially developed for veterinary use.
Iorns and Knox subsequently licensed the therapy and partnered with Ardent Animal Health to combine it with the company’s personalized cancer vaccine.
They conducted a registrational study in dogs with osteosarcoma that recently met its endpoint.
That experience contributed to their decision to establish Familiar as a company focused on developing and commercializing additional veterinary medicines across multiple therapeutic areas.
“Our goal is to give vets proven, FDA-approved treatments that change the course of serious diseases in dogs and cats, where today they often have very few options,” said Iorns, Familiar’s co-founder and CEO.
Pharmaceutical Partnerships Support Development Model
Familiar works with pharmaceutical and biotechnology companies to license veterinary rights to medicines while allowing its partners to retain human pharmaceutical rights.
The company’s development model also provides participating partners with a share of veterinary product sales.
According to Knox, Familiar’s co-founder and chief operating officer, research conducted in dogs and cats with naturally occurring diseases may also provide evidence that informs human pharmaceutical development programs.
The company has assembled a team of senior animal health drug developers who have contributed to more than 30 FDA approvals, with experience at companies including Zoetis, Elanco and Bayer Animal Health.
Familiar also has a 12-member Scientific Advisory Board comprising veterinary specialists, practicing veterinarians and animal health researchers.
Robbie Paul, CEO of Icehouse Ventures, cited the founders’ entrepreneurial experience and growing expectations for companion animal healthcare as factors supporting the investment.
Clinical Study and Partnership Information
Veterinarians and pet owners interested in learning more about Familiar’s FAM-010 canine hemangiosarcoma study can visit the company’s study information page.
Learn More About the FAM-010 Clinical Study.
Pharmaceutical and biotechnology companies interested in potential collaborations can contact Familiar at partnerships@familiartx.com.
Information sourced from Familiar Therapeutics’ company launch and seed funding press release.
